Choosing injectable PrEP for HIV prevention in Cape Town
Part of Immune system & allergy, Infections clinical trials.
This study offers three ways to prevent HIV: a shot every two months (injectable PrEP), daily pills, or a vaginal ring. Researchers in Cape Town will help you choose the option that fits your life best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must test negative for HIV at the start of the study.
- You must weigh more than 35 kilograms (77 pounds).
- You must be older than 15 years of age.
- You must live in the Cape Town study area or be there for work or school most of the time.
- You must be willing to receive an injectable medication for HIV prevention.
- You should not be allergic to any of the study products or be taking medications that interfere with them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach to help men at risk for HIV stay healthy by providing access to PrEP through a mobile app. The goal is to see if the program helps men start and stay on PrEP compared to standard care.
This study offers a new injectable medication called lenacapavir to prevent HIV. It is for people who are HIV-negative and sexually active, and want to try a long-acting injection instead of daily pills.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
This study tests different ways to take HIV prevention medicine (PrEP) for men who travel for work. It compares daily pills, pills taken only around sex, and a long-acting injection to see which works best for mobile men in sub-Saharan Africa.
Hear when a new Sexual and Reproductive Health trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.